These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38311833)

  • 1. Results from a Phase 1 Study Assessing the Pharmacokinetics of the Aldosterone Synthase Inhibitor Baxdrostat in Participants with Varying Degrees of Renal Function.
    Freeman MW; Halvorsen YD; Bond M; Murphy B; Isaacsohn J
    Clin Pharmacol Drug Dev; 2024 Apr; 13(4):410-418. PubMed ID: 38311833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers.
    Freeman MW; Bond M; Murphy B; Hui J; Isaacsohn J
    Hypertens Res; 2023 Jan; 46(1):108-118. PubMed ID: 36266539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results From a Randomized, Open-Label, Crossover Study Evaluating the Effect of the Aldosterone Synthase Inhibitor Baxdrostat on the Pharmacokinetics of Metformin in Healthy Human Subjects.
    Freeman MW; Bond M; Murphy B; Hui J; Isaacsohn J
    Am J Cardiovasc Drugs; 2023 May; 23(3):277-286. PubMed ID: 36790596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension.
    Freeman MW; Halvorsen YD; Marshall W; Pater M; Isaacsohn J; Pearce C; Murphy B; Alp N; Srivastava A; Bhatt DL; Brown MJ;
    N Engl J Med; 2023 Feb; 388(5):395-405. PubMed ID: 36342143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of vilazodone in patients with mild or moderate renal impairment.
    Boinpally R; Alcorn H; Adams MH; Longstreth J; Edwards J
    Clin Drug Investig; 2013 Mar; 33(3):199-206. PubMed ID: 23417352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension.
    Awosika A; Cho Y; Bose U; Omole AE; Adabanya U
    Expert Opin Investig Drugs; 2023; 32(11):985-995. PubMed ID: 37883217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
    Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC
    Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Safety of Imeglimin in Japanese Patients With Impaired Renal Function.
    Kitamura A; Yumizaki T; Kondo T; Sekino H; Kakuyama H
    J Clin Pharmacol; 2023 Jul; 63(7):807-816. PubMed ID: 36847203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment.
    Perera V; Abelian G; Li D; Wang Z; Zhang L; Lubin S; Bello A; Murthy B
    Clin Pharmacokinet; 2022 Oct; 61(10):1405-1416. PubMed ID: 35906349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-Dose Pharmacokinetics and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Subjects with Severe Renal Function Impairment.
    Sidharta PN; Ulč I; Dingemanse J
    Clin Drug Investig; 2019 Nov; 39(11):1117-1123. PubMed ID: 31435905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and safety of iomeprol in healthy volunteers and in patients with renal impairment or end-stage renal disease requiring hemodialysis.
    Lorusso V; Taroni P; Alvino S; Spinazzi A
    Invest Radiol; 2001 Jun; 36(6):309-16. PubMed ID: 11410750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment.
    Tayo B; Taylor L; Sahebkar F; Morrison G
    Clin Pharmacokinet; 2020 Jun; 59(6):747-755. PubMed ID: 31802404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baxdrostat: An Aldosterone Synthase Inhibitor for the Treatment of Systemic Hypertension.
    Dey S; Frishman WH; Aronow WS
    Cardiol Rev; 2023 Aug; ():. PubMed ID: 37548462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of renal impairment on the pharmacokinetics of intravenous zanamivir.
    Cass LM; Efthymiopoulos C; Marsh J; Bye A
    Clin Pharmacokinet; 1999; 36 Suppl 1():13-9. PubMed ID: 10429836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment.
    Mercier AK; Sunnåker M; Ueckert S; Pawlik T; Henricson E; Molodetskyi O; Law GC; Parker VER; Oscarsson J
    Clin Pharmacokinet; 2023 Dec; 62(12):1713-1724. PubMed ID: 37801266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.
    Tuttle KR; Hauske SJ; Canziani ME; Caramori ML; Cherney D; Cronin L; Heerspink HJL; Hugo C; Nangaku M; Rotter RC; Silva A; Shah SV; Sun Z; Urbach D; de Zeeuw D; Rossing P;
    Lancet; 2024 Jan; 403(10424):379-390. PubMed ID: 38109916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Renal Impairment on the Pharmacokinetics of a Single Oral Dose of Danuglipron in Participants With Type 2 Diabetes.
    Fediuk DJ; Gorman DN; Stoddard SA; Zhang Y; Ogden AG; Winton JA; Saxena AR
    J Clin Pharmacol; 2024 Apr; 64(4):449-460. PubMed ID: 37840155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and Safety of CSL112 (Apolipoprotein A-I [Human]) in Adults With Moderate Renal Impairment and Normal Renal Function.
    Tortorici MA; Duffy D; Evans R; Feaster J; Gille A; Mant TGK; Wright SD; D'Andrea D
    Clin Pharmacol Drug Dev; 2019 Jul; 8(5):628-636. PubMed ID: 30240132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
    Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
    Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus.
    Sarashina A; Ueki K; Sasaki T; Tanaka Y; Koiwai K; Sakamoto W; Woerle HJ; Salsali A; Broedl UC; Macha S
    Clin Ther; 2014 Nov; 36(11):1606-15. PubMed ID: 25199997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.